Medical/Pharmaceuticals
CQ Medical's Iris AirShuttle™ Patient Transfer Platform Recognized at Women in Innovation Award Showcase
AVONDALE, Pa., March 5, 2025 /PRNewswire/ -- The Iris AirShuttle™, a patient transfer platform developed by CQ Medical, is designed to streamline the transfer of patients from procedures to imaging. Recently, it was featured at theWomen in Innovation Award Showcase, an event that celebrated Profe...
2025-03-05 18:00
1678
Bioheng Therapeutics Announces FDA Clearance of IND Application for CD7 UCAR T Cell Therapy in T-ALL/LBL
BOSTON, March 5, 2025 /PRNewswire/ -- Bioheng Therapeutics US LLC ("Bioheng"), a clinical-stagebiotech company dedicated to developing innovative universal CAR-T cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) appli...
2025-03-05 14:49
2125
CordenPharma Expands Peptide Platform with more than 500 Million Euro Greenfield Facility Construction in the Basel Region of Switzerland
* CordenPharma is making a record investment of >€1 billion over the next 3 years in building and / or expanding small, medium, and large peptide manufacturing facilities acrossEurope and the US. * In Switzerland, CordenPharma will invest >€500m to construct a greenfield site for small to lar...
2025-03-05 13:30
2504
XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC
- XPOVIO® is the first and only approved XPO1 inhibitor in Indonesia. - From the second half of 2024 to now, XPOVIO® was successively approved in Thailand, Malaysia and Indonesia, significantly expanding Antengene's commercial presence in APAC. To date, XPOVIO® has been approved for multiple ind...
2025-03-05 13:00
2325
XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC
- XPOVIO® is the first and only approved XPO1 inhibitor in Indonesia. - From the second half of 2024 to now, XPOVIO® was successively approved in Thailand, Malaysia and Indonesia, significantly expanding Antengene's commercial presence in APAC. To date, XPOVIO® has been approved for multiple ind...
2025-03-05 13:00
2523
GHIT-backed Innovation Achieves Landmark: New Treatment Option for Schistosomiasis Reaches Preschool-Aged Children
TOKYO, March 5, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund is today announcing a significant milestone: the first administration of arpraziquantel to preschool-aged children inUganda, in an implementation science setting. This new pediatric treatment for schistosomi...
2025-03-05 09:00
2252
The Chinese carbon ion center Heyou Hospital selects RayStation
STOCKHOLM, March 4, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) is pleased to announce that Heyou Hospital, located in Foshan City,Guangdong Province, China, has placed an order for the treatment planning system RayStation®*. Total order value (including service contract) is RMB 51 mill...
2025-03-04 18:48
1843
Celltrion receives U.S. FDA approval for STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) biosimilars referencing PROLIA® and XGEVA®
* STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of reference products PROLIA® (denosumab) and XGEVA® (denosumab) respectively[1], [2] * The FDA approval is based on robust clinical evidence, which show no clinically meaningful differences fr...
2025-03-04 12:28
2690
Chulalongkorn University Unveils Exoskeleton Wheelchair to Aid Mobility
BANGKOK, March 4, 2025 /PRNewswire/ -- Chulalongkorn University
2025-03-04 12:16
3479
HKBU clinches four gold medals at the 15th International Invention Fair in the Middle East
HONG KONG, March 3, 2025 /PRNewswire/ -- Hong Kong Baptist University (HKBU)
won four gold medals at the 15th International Invention Fair in theMiddle East
(IIFME) held inKuwait from 16 to 19 February. It was the first time that HKBU
participated in the event.
2025-03-04 12:10
2062
DeepQure Advances Global Clinical Trials for Innovative RDN Technology
SEOUL, South Korea, March 3, 2025 /PRNewswire/ -- Breaking Barriers in Hypertension Treatment DeepQure Inc., a pioneering medical device startup, is revolutionizing the treatment of resistant hypertension with its innovative extravascular (laparoscopic approach) renal denervation (RDN) device, Hy...
2025-03-04 09:46
2111
Raziel and Fosun Pharma (by JuveStar an affiliate company of Fosun Pharma) Initiate Phase 3 Registration Trial in China for Submental Fat Reduction ("double chin")
REROVOT, Israel, March 3, 2025 /PRNewswire/ -- Raziel Therapeutics, a pharmaceutical company developing next-generation novel prescription products for the medical aesthetics market, announces phase 3 study initiation inChina for the treatment of fat reduction in the submental area. Submental fat...
2025-03-04 09:00
2029
Raziel and Fosun Pharma (by JuveStar an affiliate company of Fosun Pharma) Initiate Phase 3 Registration Trial in China for Submental Fat Reduction ("double chin")
REROVOT, Israel, March 4, 2025 /PRNewswire/ -- Raziel Therapeutics, a pharmaceutical company developing next-generation novel prescription products for the medical aesthetics market, announces phase 3 study initiation inChina for the treatment of fat reduction in the submental area. Submental fat...
2025-03-04 09:00
1970
CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of CS2009, a PD-1/VEGF/CTLA-4 Trispecific Antibody
SUZHOU, China, March 3, 2025 /PRNewswire/ --CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced thatthe first patient has been successfully dosed in the global multicenter P...
2025-03-04 08:10
3521
Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum
MELBOURNE, Australia and INDIANAPOLIS, Ind., March 4, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) invites investors to join a webinar showcasing the Company's late-stage and next-generation radiotherapeutic candidates in urologic oncology. In ...
2025-03-04 05:58
2299
Frost & Sullivan Recognizes Cynerio for Advancing Healthcare Cybersecurity with Its NDR-H Solution to Combat Cyber Threats
Cynerio's NDR-H Solution enables deep packet inspection, comprehensive network traffic analysis with real-time threat detection and response, and proactive auto identification and analysis of connected devices. SAN ANTONIO, March 3, 2025 /PRNewswire/ -- Frost & Sullivan recently analyzed the hea...
2025-03-03 22:00
1980
Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept
* Frazier Life Sciences launches Callio Therapeutics based on multi-payload antibody-drug conjugate technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience * Financing led by Frazier Life Sciences with significant participation from Jeito Capital alongside o...
2025-03-03 22:00
3112
Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics
* First ever head-to-head comparison of gut microbiome changes associated with ibezapolstat (IBZ) to other anti-CDI antibiotics in a germ-free mouse model * Changes in alpha and beta microbiome diversities following IBZ treatment were less pronounced compared to those observed in vancomycin (VA...
2025-03-03 21:00
1789
DrFirst Recognized for Enabling Technology Leadership in Healthcare by Frost & Sullivan
Leading the Way in Healthcare Innovation Across the Medication Journey SAN ANTONIO, March 3, 2025 /PRNewswire/ -- DrFirst, a leading innovator in healthcare technology, has been honored with the prestigious Enabling Technology Leadership Award by Frost & Sullivan. This recognition highlights how...
2025-03-03 21:00
1665
METiS Pharmaceuticals Appoints Mark Herbert as Chief Business Officer
HANGZHOU, China, March 3, 2025 /PRNewswire/ -- METiS Pharmaceuticals, a clinical-stage, AI-driven biotechnology company specializing in innovative drug delivery technologies, today announced the appointment ofMark Herbert as Chief Business Officer (CBO), effectiveJanuary 22, 2025. In this role, M...
2025-03-03 16:20
2371
Week's Top Stories
Most Reposted
Agoda Opens New Office at One Bangkok, Enhancing Its Technology Hub in Thailand
[Picked up by 321 media titles]
2026-04-09 13:00
Visa Opens the Door to AI-Driven Shopping for Businesses Worldwide
[Picked up by 312 media titles]
2026-04-09 09:00Visa cements global K-pop connection as Worldwide Tour Sponsor for "BTS WORLD TOUR 'ARIRANG'"
[Picked up by 307 media titles]
2026-04-06 10:00
Tata Power Collaborates with Databricks to Build Future-Ready Data and AI Platform to Accelerate Energy Transition
[Picked up by 302 media titles]
2026-04-10 11:13
UTP Advances Across Key Disciplines in QS World University Rankings By Subject 2026 - Petroleum Engineering Among World's Top 10
[Picked up by 300 media titles]
2026-04-06 16:46
Most Read
Ridgetech, Inc. Announces 1-for-150 Reverse Share Split
2026-04-04 00:00
5551
NYSE Content Update: Starfish Space Adds Over $100 Million in Funding to Boost Growth
2026-04-07 21:06
5018
Elevate Easter Celebrations: Nework Introduces MoveMate Series Portable TVs for Effortless Family Moments
2026-04-04 00:00
4846
